EA6134

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Contact phone
180.096.85570
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Melanoma
Webform